Please join me for the upcoming National Institutes for Health Conference on Advancing ME/CFS Research: Identifying Targets for Intervention and Learning from Long COVID. Open Medicine Foundation is proud to be sponsoring the lunches at the conference to provide an opportunity for researchers and community members in attendance to network and come together to share insights, and contribute to the advancement of ME/CFS and Long COVID research. Please come visit me at our table during lunch and say hello!
Conference Goals:
The primary goals of this conference are to foster collaboration among researchers, clinicians, and advocates, with a focus on advancing our understanding of ME/CFS and the overlapping complexities presented by Long COVID.
Along with other esteemed speakers, the following members of OMF’s Scientific Advisory Board will be speaking as well:
Lucinda Bateman, MD (Bateman Horne Center, Director OMF MERC)
Mark M. Davis, PhD (Standford University)
Maureen Hanson, PhD (Cornell University)
Alain Moreau, PhD (University of Montreal, Director OMF Montreal Collaboration)
David Systrom, MD (Harvard, BWH, OMF Co-Director Harvard Collaboration)
By bringing together experts from various disciplines, the conference aims to identify potential targets for intervention and share valuable insights into both diseases. This collaborative effort is instrumental in propelling research forward and paving the way for improved diagnostics, treatments, and overall patient care.
Event Details:
December 12 and 13
National Institutes of Health
Masur Auditorium (Building 10)
10 Center Drive
Bethesda, MD 20814
To register for the conference in person or virtually please visit the conference Registration Link. Early registration is encouraged, as space for in-person attendance is limited.
We hope you will consider attending the conference if you are able. Thank you for your continued support and dedication to advancing ME/CFS and Long COVID research.
Donate your appreciated stock directly to OMF and you can receive an immediate income-tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).